CG Oncology Inc
CGON
查看详细走势图
39.840USD
-0.300-0.75%
收盘 12/26, 16:00（美东）报价延迟15分钟
3.12B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.75%
5天
+4.84%
1月
-12.46%
6月
+52.88%
今年开始到现在
+38.91%
1年
+40.78%
查看详细走势图
TradingKey CG Oncology Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
CG Oncology Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名54/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价71.67。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CG Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
14
位分析师
买入
评级
71.667
目标均价
+67.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CG Oncology Inc亮点
亮点风险
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
业绩高增长
公司营业收入稳步增长，连续3年增长496.34%
业绩增长期
公司处于发展阶段，最新年度总收入1.14M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.14M美元
估值合理
公司最新PE估值-19.65，处于3年历史合理位
机构加仓
最新机构持股88.33M股，环比增加0.51%
史蒂文·科恩持仓
明星投资者史蒂文·科恩持仓，最新持仓市值1.52M
CG Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CG Oncology Inc简介
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
公司代码CGON
公司CG Oncology Inc
CEOKuan (Arthur)
网址https://www.cgoncology.com/
常见问题
CG Oncology Inc(CGON)的当前股价是多少？
CG Oncology Inc(CGON)的当前股价是 39.840。
CG Oncology Inc的股票代码是什么？
CG Oncology Inc的股票代码是CGON。
CG Oncology Inc股票的52周最高点是多少？
CG Oncology Inc股票的52周最高点是46.010。
CG Oncology Inc股票的52周最低点是多少？
CG Oncology Inc股票的52周最低点是14.800。
CG Oncology Inc的市值是多少？
CG Oncology Inc的市值是3.12B。
CG Oncology Inc的净利润是多少？
CG Oncology Inc的净利润为-88.04M。
现在CG Oncology Inc(CGON)的股票是买入、持有还是卖出？
根据分析师评级，CG Oncology Inc(CGON)的总体评级为买入，目标价格为71.667。
CG Oncology Inc(CGON)股票的每股收益（EPS TTM）是多少
CG Oncology Inc(CGON)股票的每股收益（EPS TTM）是-2.043。
相关品种
